Pulmonary position cryopreserved homograft in non-Ross patients: how to improve the results?
Authors:
Open Access
- 9 May 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 42 (6) , 981-987
Abstract
The outcomes of homografts (HGs) in the reconstruction of the right ventricular outflow tract (RVOT) in non-Ross patients are often considered disappointing, compared with Ross patients; and the risk factors for HG degeneration are still controversial. The objective of this study was to determine the durability and prognostic factors related to the HGs implanted in non-Ross patients and to propose potential ways to improve the results. A retrospective study (1993–2010) included 115 consecutive non-Ross patients who received a HG for RVOT reconstruction. The median age at implantation was 2.8 years (4 days–58 years). The main heart defects were pulmonary atresia with ventricular septal defect (n = 40; 34%), truncus arteriosus (n = 28; 24%) and tetralogy of Fallot (n = 23; 20%). Thirty-eight percent had preoperative pulmonary hypertension. A low-dose corticosteroid therapy was used during the postoperative period in patients displaying a HG-related inflammatory response (no septic context) (n = 11). The median diameter of the implanted HG was 22 mm (range 9–30 mm). The median age of the HG donor was 14 years (range 0.5–65 years). ABO compatibility rules were not systematically respected for the HG implantation: 43% of the implanted HGs were ABO compatible with the recipient. The endpoints were HG stenosis (peak gradient ≥20 mmHg), regurgitation (moderate or severe), dysfunction (peak gradient ≥ 50 mmHg or regurgitation moderate or severe) and failure (explantation or balloon dilation). Freedom from HG explantation and failure were 89 and 80% at 5 years, and 76 and 69% at 10 years, respectively. HG donor age P = 0.012], preoperative pulmonary hypertension (HR: 3; P = 0.02) and HG mismatch (HR: 5; P = 0.04) were multivariate risk factors for HG stenosis, regurgitation and failure, respectively. HG diameter P < 0.001), dysfunction (HR: 9; P = 0.02) and failure (HR: 5; P = 0.03). ABO incompatibility increased the risk of HG stenosis (HR: 4; P = 0.009) and dysfunction (HR: 2; P = 0.04). The use of corticosteroids significantly protected against the risk of HG regurgitation (HR: 0.08; P = 0.04) in the multivariate analysis. The cryopreserved HG implanted to reconstruct the RVOT in non-Ross patients remains one of the most acceptable options in this specific non-Ross population. The outcomes of HGs in non-Ross patients might be improved by implanting an ABO-compatible HG with an adapted diameter, coming from a donor >30 years and by optimizing the perioperative afterload of the HG.Keywords
This publication has 25 references indexed in Scilit:
- Re-interventions on the autograft and the homograft after the Ross operation in children☆European Journal of Cardio-Thoracic Surgery, 2010
- Evaluation of 188 consecutive homografts implanted in pulmonary position after 20 years☆☆☆European Journal of Cardio-Thoracic Surgery, 2007
- Pulmonary position cryopreserved homografts: Durability in pediatric Ross and non-Ross patientsThe Journal of Thoracic and Cardiovascular Surgery, 2005
- Right Ventricular Outflow Tract Reconstruction With an Allograft Conduit in Non-Ross Patients: Risk Factors for Allograft Dysfunction and FailureThe Annals of Thoracic Surgery, 2005
- Blood group incompatibility and accelerated homograft fibrocalcificationsThe Journal of Thoracic and Cardiovascular Surgery, 2004
- Reoperative homograft right ventricular outflow tract reconstructionThe Annals of Thoracic Surgery, 2001
- Cryopreserved homograft valves in the pulmonary position: Risk analysis for intermediate-term failureThe Journal of Thoracic and Cardiovascular Surgery, 1999
- Fate Of Subpulmonary Homograft Conduits: Determinants Of Latehomograft FailureThe Journal of Thoracic and Cardiovascular Surgery, 1998
- Factors in the early failure of cryopreserved homograft pulmonary valves in children: Preserved immunogenicity?The Journal of Thoracic and Cardiovascular Surgery, 1996
- Allograft degeneration in infant pulmonary valve allograft recipientsEuropean Journal of Cardio-Thoracic Surgery, 1993